Holen Sie sich die Stockscreener-App
2.63
4.17%
0.11
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
April 2nd Options Now Available For Iovance Biotherapeutics (IOVA) - Nasdaq
Can Iovance Biotherapeutics Inc grow without dilutionJuly 2025 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 - The Manila Times
Iovance Biotherapeutics to Host Conference Call for Q4 and Full Year 2025 Financial Results on February 24, 2026 - Quiver Quantitative
Market Wrap: Will Iovance Biotherapeutics Inc benefit from green energy policiesCPI Data & Expert Curated Trade Setups - baoquankhu1.vn
Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Volatility - Yahoo Finance
Is It Time To Reconsider Iovance Biotherapeutics (IOVA) After Prolonged Share Price Weakness - Yahoo Finance
Iovance’s Amtagvi Data and Valuation Gap Refocus Investor Attention - Yahoo Finance
Does The Recent Share Price Slump Make Iovance Biotherapeutics (IOVA) Look More Attractive? - Sahm
Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure - Insider Monkey
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Melanoma cell therapy shows 52% response when used earlier - stocktitan.net
Iovance Biotherapeutics Announces Promising Real-World Data for Amtagvi® in Advanced Melanoma Treatment - Quiver Quantitative
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma - GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA) - The Globe and Mail
Assessing Iovance Biotherapeutics (IOVA) Valuation As It Transitions To Commercial Stage With First Product Launch Plans - Sahm
Iovance down 18% warning it could be impacted by geopolitical instability, inflation - MSN
Former Iovance CEO Maria Fardis lands at AirNexis with $200 millionBizwomen - The Business Journals
She raised more than $1 billion for Iovance. Now, Maria Fardis has a new startup and a $200 million investment - The Business Journals
Performance Recap: Why is Iovance Biotherapeutics Inc stock going upJuly 2025 Opening Moves & Capital Efficiency Focused Strategies - baoquankhu1.vn
Trade Recap: Whats the beta of Iovance Biotherapeutics Inc stockOptions Play & Real-Time Sentiment Analysis - baoquankhu1.vn
Iovance Biotherapeutics Inc. (IOVA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Iovance Biotherapeutics (IOVA): Investor Outlook Reveals 217% Potential Upside - DirectorsTalk Interviews
Aug Reactions: Will Iovance Biotherapeutics Inc benefit from AI trendsJobs Report & Target Return Focused Stock Picks - baoquankhu1.vn
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.5%Should You Sell? - MarketBeat
Financial Investigation Sparks Potential Reforms at Iovance Biotherapeutics - StocksToTrade
Is Iovance Biotherapeutics Inc. showing insider buyingJuly 2025 Drop Watch & Low Risk Profit Maximizing Plans - mfd.ru
Activity Recap: Whats the beta of Iovance Biotherapeutics Inc stock2025 Historical Comparison & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Autologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Recap Report: Whats the beta of Iovance Biotherapeutics Inc stockGap Up & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 7.4% HigherStill a Buy? - MarketBeat
IOVA Shares Jump 8% — What’s Retail Expecting? - Stocktwits
Iovance Biotherapeutics Sets Stage for Global TIL Leadership with Stock Induction Moves - StocksToTrade
Short Squeeze: Can LANDP sustain its profitability2025 Risk Factors & Verified Short-Term Plans - baoquankhu1.vn
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Unpacking a Potential 210% Upside Amidst Biotech Innovations - DirectorsTalk Interviews
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Is Expected To Breakeven In The Near Future - 富途牛牛
How Investors Are Reacting To Iovance Biotherapeutics (IOVA) FDA Boost For Its TIL Cancer Platform - simplywall.st
Advanced Melanoma Pipeline Expands With 60+ Investigational Therapies and 55+ Active Developers, Reports DelveInsight - Barchart.com
Advanced Melanoma Pipeline Expands With 60+ Investigational - openPR.com
Bull Run: Is Iovance Biotherapeutics Inc showing insider buyingEarnings Performance Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Assessing Iovance Biotherapeutics (IOVA) Valuation After Clinical Trial Progress And New FDA Designations - Sahm
What drives Iovance Biotherapeutics Incs stock priceTrade Entry Report & Community Consensus Stock Picks - baoquankhu1.vn
Trend Report: Will TNON benefit from seasonalityPortfolio Gains Summary & Stepwise Trade Execution Plans - baoquankhu1.vn
Dow Update: Can Iovance Biotherapeutics Inc deliver consistent EPS growthPortfolio Performance Report & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Why Iovance Biotherapeutics Stock Got Mashed on Monday - MSN
Analyst Boosts Iovance’s Price Target Amid Positive Market Moves - timothysykes.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance Biotherapeutics Stock Surges Amid Strategic Moves - StocksToTrade
Is Iovance Biotherapeutics (IOVA) A Potential Opportunity After Multi Year Share Price Slide - Sahm
Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed - Yahoo Finance
Biotech Iovance offers 97,710 stock options to 17 new hires at $2.22 - Stock Titan
Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns - Yahoo Finance
Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory - Finviz
Iovance gets conditional Health Canada approval for Amtagvi - MSN
0.49%
2.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):